PYC · ASX

PYC Therapeutics Limited (ASX:PYC)

AU$0.91

 0.062 (7.353%)
ASX:Live
18/09/2025 03:21:13 PM
Volume Spike Near Support Near 52 Week Low Hammer Bullish HALO Ords +6
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

PYC Overview

PYC Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Strong

About PYC

Website

PYC Therapeutics Limited

Telephone

61.8.6151.0992

Address

6 Verdun Street Harry Perkins Institute Nedlands, Western Australia (WA) 6009

Description

PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. It develops intracellular biological therapeutics including its own preclinical oncology payloads, using its proprietary cell Functional Penetrating Phylomers. The company was founded by Richmond Miles Hopkins and Paul Michael Watt on October 9, 2001, and is headquartered in Nedlands, Australia.

PYC Price Chart

Key Stats

Market Cap

AU$495.77M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.85 - 2.09

Trade Value (12mth)

AU$179,325.00

1 week

-30.33%

1 month

-35.36%

YTD

-32.7%

1 year

-41.06%

All time high

6.46

Key Fundamentals

EPS 3 yr Growth

134.80%

EBITDA Margin

N/A

Operating Cashflow

-$52m

Free Cash Flow Return

-41.00%

ROIC

-40.00%

Interest Coverage

-1,202.20

Quick Ratio

14.40

Other Data

Shares on Issue (Fully Dilluted)

541m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

PYC Announcements

Latest Announcements

Date Announcements

17 September 25

Change of Managing Director

×

Change of Managing Director

05 September 25

ADOA Program - Presentation of Clinical Data at NOSA 2025

×

ADOA Program - Presentation of Clinical Data at NOSA 2025

29 August 25

PKD Program - Presentation of Safety Data at ANZSN

×

PKD Program - Presentation of Safety Data at ANZSN

28 August 25

Appendix 4E

×

Appendix 4E

28 August 25

2025 Annual Report to Shareholders

×

2025 Annual Report to Shareholders

28 August 25

Appendix 4G

×

Appendix 4G

28 August 25

2025 Corporate Governance Statement

×

2025 Corporate Governance Statement

08 August 25

Approval to Escalate Dosing in Kidney Disease Clinical Trial

×

Approval to Escalate Dosing in Kidney Disease Clinical Trial

01 August 25

Q3 2025 Investor Webinar Presentation

×

Q3 2025 Investor Webinar Presentation

28 July 25

Q3 Investor Webinar 1 August 2025

×

Q3 Investor Webinar 1 August 2025

21 July 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

07 July 25

Approval to Progress Kidney Disease Trial to Next Stage

×

Approval to Progress Kidney Disease Trial to Next Stage

27 June 25

Fourth Drug Program Progressing to Human Trials

×

Fourth Drug Program Progressing to Human Trials

23 June 25

FDA Alignment on Registrational Trial Design RP11 Program

×

FDA Alignment on Registrational Trial Design RP11 Program

11 June 25

SRC Approves Dose Escalation in ADOA Clinical Trial

×

SRC Approves Dose Escalation in ADOA Clinical Trial

30 May 25

Investor Webinar Presentation

×

Investor Webinar Presentation

26 May 25

Approval to Escalate Dosing in Kidney Disease Trial

×

Approval to Escalate Dosing in Kidney Disease Trial

23 May 25

Notification of cessation of securities - PYC

×

Notification of cessation of securities - PYC

13 May 25

Q2 Investor Webinar 30 May 2025

×

Q2 Investor Webinar 30 May 2025

02 May 25

Foundation Fighting Blindness Presentation Materials

×

Foundation Fighting Blindness Presentation Materials

28 April 25

Presentation of Clinical Proof of Concept in Lead Program

×

Presentation of Clinical Proof of Concept in Lead Program

28 April 25

Change in substantial holding

×

Change in substantial holding

24 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

23 April 25

Application for quotation of securities - PYC

×

Application for quotation of securities - PYC

17 April 25

Completion of Entitlement Offer

×

Completion of Entitlement Offer

10 April 25

First Subject Dosed in PKD Clinical Trial

×

First Subject Dosed in PKD Clinical Trial

PYC Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 -0.10 -0.10 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 -0.10 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.1 -36.5 -5.5 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.06 -0.08 -0.08 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.08 -0.10 -0.10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -62.9 -21.4 -7.1 Lock Lock Lock
     Yield % Lock Lock Lock Lock -13.9 -8.2 -8.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.08 0.17 0.29 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.07 0.16 0.28 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.3 141.0 74.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 327 396 501 Lock Lock Lock
Basic m Lock Lock Lock Lock 327 396 501 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 38 59 75 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -1 -1 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -5.1 -21.1 -4.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -38 -59 -75 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.3 -55.1 -26.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -39 -60 -76 Lock Lock Lock
     Growth % Lock Lock Lock Lock -29.6 -54.3 -25.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -39 -56 -75 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -16 -18 -23 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -23 -38 -50 Lock Lock Lock
     Growth % Lock Lock Lock Lock -64.4 -65.5 -33.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -24 -39 -52 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 11 90 139 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -25 -39 -53 Lock Lock Lock
     Growth % Lock Lock Lock Lock -12.4 -56.1 -35.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 16 67 153 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 37 91 183 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -15 -66 -152 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 9 10 13 Lock Lock Lock
Equity $m Lock Lock Lock Lock 28 80 170 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 28 81 170 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.3 191.5 109.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -61.3 -41.3 -27.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -82.1 -46.9 -29.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -112.0 -108.9 -60.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -67.1 -69.1 -40.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -71.9 -70.7 -41.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock -1,402.9 -1,206.2 -1,202.2 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.4 1.1 2.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -55.0 -81.7 -89.7 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.8 9.4 14.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.8 9.4 14.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 48.9 78.1 86.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -290.5 -423.7 -418.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -61.3 -41.3 -27.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -82.1 -46.9 -29.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -82.1 -46.9 -29.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,550.6 2,127.0 2,664.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,550.6 -2,127.0 -2,664.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.15%

Value ($M)

1

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

PYC Shortsell

Frequently Asked Questions

The current share price of PYC Therapeutics Limited (PYC:ASX) is AU$0.91.
The 52-week high share price for PYC Therapeutics Limited (PYC:ASX) is AU$2.09.
The 52-week low share price for PYC Therapeutics Limited (PYC:ASX)? is AU$0.85.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) has a franking level of 0.0%.
PYC Therapeutics Limited (PYC:ASX) is classified in the Healthcare.
The current P/E ratio for PYC Therapeutics Limited (PYC:ASX) is .
The current share price of PYC Therapeutics Limited (PYC:ASX) is AU$0.91.
The 52-week high share price for PYC Therapeutics Limited (PYC:ASX) is AU$2.09.
The 52-week low share price for PYC Therapeutics Limited (PYC:ASX)? is AU$0.85.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) does not pay a dividend.
PYC Therapeutics Limited (PYC:ASX) has a franking level of 0.0%.
PYC Therapeutics Limited (PYC:ASX) is classified in the Healthcare.
The current P/E ratio for PYC Therapeutics Limited (PYC:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.